Windlas Biotech IPO will be open from 4 Aug 2021 and close on 6 Aug 2021. Windlas Biotech IPO GMP Kostak rate and Subject to Sauda updated as of Today. Windlas Biotech Grey Market Premium has been Started with Low Premium Rates, We need to wait for the rates to change with the Market Sentiment in a few days or to Stabilize the Rates.
Windlas Biotech Ltd company is in the domestic pharmaceutical formulation contract development and manufacturing business. And it is one of the top five players in pharmaceutical formulation contracts, development, and manufacturing in India. The company formulations sell their branded products to many in the CDMO industry, in addition to providing services and products in the CDMO market, in the business generics and OTC markets, as well as in export general products.
Windlas Biotech IPO Issue size of ₹401.53 Crores, in which Fresh Issue of ₹165 Crores and Offer For Sale of ₹236.53 Crores and issue price band has been fixed at ₹448-₹460 Per Share. The Windlas Biotech IPO is to be listed Soon on NSE and BSE.
What is Windlas Biotech IPO GMP Today?
■ The Windlas Biotech IPO GMP Today Or Grey Market Premium is ₹75-₹80.
What is Windlas Biotech IPO Kostak Rates Today?
■ The Windlas Biotech IPO Kostak rate is ₹0.
What is Windlas Biotech IPO Subject to Sauda Price Today?
■ The Windlas Biotech IPO Subject to Sauda rates is ₹0.
Windlas Biotech IPO Approximately Returns?
■ The Windlas Biotech IPO’s approximate return is 25%-30%. And it can also change according to the Market Sentiment.
Windlas Biotech IPO GMP, Kostak,& Subject to Sauda :
|16 Aug 2021||List-₹437||₹0||₹0|
|15 Aug 2021||₹75-₹80||₹0||₹0|
|14 Aug 2021||₹75-₹80||₹0||₹0|
|13 Aug 2021||₹80-₹85||₹0||₹0|
|12 Aug 2021||₹85-₹90||₹0||₹0|
|11 Aug 2021||₹35-₹45||₹0||₹0|
|10 Aug 2021||₹80-₹85||₹0||₹0|
|9 Aug 2021||₹75-₹80||₹0||₹0|
|8 Aug 2021||₹80-₹90||₹0||₹0|
|7 Aug 2021||₹80-₹90||₹0||₹0|
|6 Aug 2021||₹120-₹130||₹0||₹0|
|5 Aug 2021||₹120-₹130||₹0||₹0|
|4 Aug 2021||₹120-₹130||₹0||₹0|
|3 Aug 2021||₹140-₹150||₹0||₹0|
|2 Aug 2021||₹140-₹150||₹0||₹0|
|1 Aug 2021||₹140-₹150||₹0||₹0|
|31 July 2021||₹140-₹150||₹0||₹0|
|30 July 2021||₹140-₹150||₹0||₹0|
|29 July 2021||₹0||₹0||₹0|
|28 July 2021||₹0||₹0||₹0|
|27 July 2021||₹0||₹0||₹0|
|26 July 2021||₹0||₹0||₹0|
|25 July 2021||₹0||₹0||₹0|
Windlas Biotech IPO Date & Price Band & Details :
|IPO Open :||4 Aug 2021|
|IPO Close :||6 Aug 2021|
|IPO Size :||₹401.53. Cr|
|Face Value :||₹5 Rs. Equity Share|
|Price Band :||₹448–₹460 Per Share|
|Listing On :||BSE, NSE|
|Issue Size :||₹401.53. Cr|
|Fresh Issue :||₹165 Cr|
|Offer For Sale :||₹236.53. Cr|
Windlas Biotech IPO Market Lot :
Windlas Biotech IPO Minimum Market lot is 1 Lot with 30 shares with ₹13,800 Application amount. The retail investors can apply up to 14 lots with 420 Shares or ₹193,200 amounts.
|Minimum Lot Size :||1 Lot|
|Minimum Share :||13|
|Minimum Amount :||₹13,800|
|Maximum Lot Size :||14 Lot|
|Maximum shares :||420|
|Maximum Amount :||₹193,200|
Windlas Biotech IPO Shares Offer :
A total of 87,29,023 shares are to be bid for the public issue by Windlas Biotech IPO with 35,86,956 for Fresh issue and 51,42,067 for an offer for sale Shares.
|Fresh issue :||35,86,956||₹165 Cr|
|Offer For Sale :||51,42,067||₹236.53 Cr|
Windlas Biotech IPO Reservation :
Windlas Biotech IPO Total Reservation of – shares are to be bid for the public issue by Windlas Biotech IPO with 43,64,511 for QIB and 13,09,352 for NII 30,55,170 For RII & – Shares EMP.
|QIB :||50 %||43,64,511||₹200.76 Cr|
|NII :||15 %||13,09,352||₹60.23 Cr|
|RII :||35 %||30,55,170||₹140.53 Cr|
|EMP :||– %||–||₹|
|Total :||100 %||87,29,023||₹401.53 Cr|
Windlas Biotech IPO Dates :
Windlas Biotech IPO Date is 4 Aug 2021 and closes on 6 Aug 2021. The allotment will be finalized on 11 Aug 2021 and the IPO may list on 17 Aug 2021.
|Open Date :||4 Aug 2021|
|Close Date :||6 Aug 2021|
|Allotment Date :||11 Aug 2021|
|Refund Date :||12 Aug 2021|
|Share Credit Date :||13 Aug 2021|
|Listing Date :||17 Aug 2021|
Windlas Biotech Company Financial Report (Cr) :
About Windlas Biotech Company
Our Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by our Shareholders on April 3, 2021, and the name of our Company was changed to ‘Windlas Biotech Limited’. A fresh certificate of incorporation dated April 15, 2021, consequent upon change of name on conversion to a public limited company was granted by the Registrar of Companies, Uttarakhand at Dehradun.
We are amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue (Source: CRISIL Report). With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances, and low solubility.
|Read also: All Upcoming IPO Grey Market Premium 2021|
we provide a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost. In Fiscal 2020, our market share was approximately 1.5% in terms of revenue in the domestic formulations CDMO industry (Source: CRISIL Report). In addition to providing services and products in the CDMO market, we also sell our own branded products in the trade generics and OTC markets as well as export generic products to several countries.
|Read also:- Share Buyback List 2021|
CDMO Services and Products. Our CDMO Services and Products SBV is focused on providing products and services across a diverse range of pharmaceutical and nutraceutical generic products for Indian and multinational pharmaceutical companies who market such products under their own brand names to the end-users. In Fiscal 2020 and the nine months ended December 31, 2020, our CDMO Services and Products SBV accounted for 87.36% and 85.73%, respectively, of our total revenue from operations. Revenues from CDMO Services and Products SBV increased by 23.12% from ₹ 2,233.68 million in the nine months ended December 31, 2019, to ₹ 2,750.07 million in the nine months ended December 31, 2020.
Windlas Biotech IPO GMP FAQs :
How much is Windlas Biotech IPO GMP Today?
Windlas Biotech IPO GMP Today is ₹75-₹80.
How much is Windlas Biotech IPO Grey Market Premium?
Windlas Biotech IPO is Grey Market Premium ₹75-₹80.
What is Windlas Biotech IPO Kostak Rate?
Windlas Biotech IPO Kostak Rate is ₹0.
What is Windlas Biotech IPO Subject to Sauda?
Windlas Biotech IPO Subject to Deals is ₹0.
What are Windlas Biotech IPO Approx Returns?
Windlas Biotech IPO approx Returns is 25%-30%. And it can also change according to the Market Sentiment.
|Windlas Biotech IPO Details: Click Here|
Windlas Biotech IPO Subscription: Click Here
Windlas Biotech IPO Allotment: Click Here
Windlas Biotech IPO Listing: Click Here
All Windlas Biotech IPO-related links are available here. If you want to know the details then click on Click Here Link.
Disclaimer: STOCK MARKET INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.